Active Versus Expectant Management of the Third Stage of Labor
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if giving oxytocin immediately after delivery causes less bleeding, transfusion needs and hastens delivery of placenta.
| Condition | Intervention |
|---|---|
|
Postpartum Hemorrhage |
Procedure: Active management of the third stage of labor Procedure: Expectant management of the third stage of labor Drug: Oxytocin and gentle cord traction with fundal massage Drug: Oxytocin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A Randomized Trial of Active Versus Expectant Management of the Third Stage of Labor |
- Incidence of postpartum hemorrhage, defined as estimated blood loss (EBL) 500mL or greater [ Time Frame: reported immediately after delivery ] [ Designated as safety issue: No ]
- Mean change in hematocrit from before delivery to the first postpartum day [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- Rate of maternal blood transfusion [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
- Duration of the third stage of labor [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]
- Incidence of retained placenta [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
| Enrollment: | 218 |
| Study Start Date: | August 2002 |
| Study Completion Date: | July 2006 |
| Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
|
Procedure: Active management of the third stage of labor
standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
Drug: Oxytocin and gentle cord traction with fundal massage
standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
|
|
2
Expectant management of the third stage of labor
|
Procedure: Expectant management of the third stage of labor
standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
Drug: Oxytocin
standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
|
Detailed Description:
Postpartum hemorrhage is the leading cause of maternal mortality worldwide. During the third stage of labor, the period following the delivery of the baby until the delivery of the placenta, the patient is at increased risk for blood loss. Controversy remains as to the optimal method of delivering the placenta. Two predominant, yet very different, strategies have emerged. Expectant management is most commonly used in the United States. This includes waiting for signs of placental separation, followed by maternal pushing to expel the placenta. Then uterotonic agents are administered,usually oxytocin. This is in contrast to active management, which consists of uterotonic administration immediately following delivery of the fetus, in association with gentle umbilical cord traction and fundal massage. This is the predominant practice in the United Kingdom, where the uterotonic agents of choice are either oxytocin alone, or a combination of oxytocin and ergometrine.
Comparison: Active management with oxytocin to expectant management of the third stage of labor on the effect of postpartum hemorrhage.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Singleton gestation
- Cephalic presentation
- >37 weeks gestation
- >16 years of age
Exclusion Criteria:
- Multiple gestation
- Breech presentation
- Blood dyscrasias
- Multiparous females Para >5
- Placenta previa
- Patients on anticoagulants
- Previous history of postpartum hemorrhage
- IUFD
- Non-reassuring fetal heart rate pattern
Contacts and Locations| United States, Delaware | |
| Christiana Care Health System | |
| Newark, Delaware, United States, 19718 | |
| Principal Investigator: | Danielle E Castagnola, MD | Christiana Care Health System |
More Information
No publications provided
| Responsible Party: | Danielle Castagnola, Christiana Care Health System |
| ClinicalTrials.gov Identifier: | NCT00473707 History of Changes |
| Other Study ID Numbers: | 26008 |
| Study First Received: | May 14, 2007 |
| Last Updated: | May 14, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Christiana Care Health Services:
|
Third stage of labor |
Additional relevant MeSH terms:
|
Hemorrhage Postpartum Hemorrhage Pathologic Processes Obstetric Labor Complications Pregnancy Complications Puerperal Disorders Uterine Hemorrhage |
Oxytocin Oxytocics Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013